Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bai

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Bioorganic & Medicinal Chemistry Letters|May 10, 2006
Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor XaJohn M Fevig, Joseph Cacciola, Joseph Buriak, et al.
Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University|February 17, 2009
[Laparoscopic radical cystectomy and detenial sigmoid colon orthotopic neobladder reconstruction for bladder tumor in a 3-year-old boy]Chun-xiao Liu, Shao-bo Zheng, Kai Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromesJorge Cortes, Stefan Faderl, Elihu Estey, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2006
Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor XaYun-Long Li, John M Fevig, Joseph Cacciola, et al.
Applied Optics|February 3, 2016
Polarization-independent plasmonic subtractive color filtering in ultrathin Ag nanodisks with high transmissionX L Hu, L B Sun, Beibei Zeng, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2007
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humansMingxin Qian, Stephen A Bai, Bernice Brogdon, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Journal of Pharmaceutical Sciences|October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerationsKan He, Mingxin Qian, Harvey Wong, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Bioorganic & Medicinal Chemistry Letters|May 10, 2006
Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor XaJohn M Fevig, Joseph Cacciola, Joseph Buriak, et al.
Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University|February 17, 2009
[Laparoscopic radical cystectomy and detenial sigmoid colon orthotopic neobladder reconstruction for bladder tumor in a 3-year-old boy]Chun-xiao Liu, Shao-bo Zheng, Kai Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromesJorge Cortes, Stefan Faderl, Elihu Estey, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2006
Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor XaYun-Long Li, John M Fevig, Joseph Cacciola, et al.
Applied Optics|February 3, 2016
Polarization-independent plasmonic subtractive color filtering in ultrathin Ag nanodisks with high transmissionX L Hu, L B Sun, Beibei Zeng, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2007
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humansMingxin Qian, Stephen A Bai, Bernice Brogdon, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Journal of Pharmaceutical Sciences|October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerationsKan He, Mingxin Qian, Harvey Wong, et al.
Pageof 8